LPS-Pro Lipopolysaccharide Lipid A Profiling to Guide Microbiome-Supported Immunotherapy in Melanoma
- Coordinator
- Universita Degli Studi Di Napoli Federico Ii, Italy
- Runs
- 1 January 2027 to 30 June 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101334827
What the project is doing
In the project's own words, from its summary on CORDIS.
Understanding how gut microbiota shapes host physiology is central to biomedicine. Yet current microbiome studies largely infer function from genetic signatures rather than directly measuring biochemical outputs. This limitation becomes critical in interventional settings such as faecal microbiota transplantation (FMT) in oncology, where donor-to-recipient transfer can alter immune tone in ways not captured by taxonomy alone.
Among key microbial immune modulators are lipopolysaccharides (LPS) from Gram-negative bacteria. The ERC StG DEBUGGING-LPS demonstrated that gut microbiota-derived LPS are not chemically equivalent and that specific LPS lipid A structural features dictate pro- or non-inflammatory output. However, this molecular information is not resolved in current microbiome monitoring approaches, limiting interpretation of microbiome-based interventions like FMT.Building on our validated lipid A profiling workflow and preliminary data in melanoma patients, LPS-Pro will prototype and validate a multiplexed platform for longitudinal lipid A profiling in faecal samples.
By enabling chemistry-resolved and decision-oriented monitoring of Gram-negative inflammatory signals, LPS-Pro will contribute to more informed donor selection, more efficient therapy monitoring, and improved risk stratification in melanoma. To strengthen our science case (A), we will convert the validated lipid A extraction and MALDI-TOF workflow into a multiplexed format; implement internal references and decision criteria to ensure robustness and reproducibility; and use functional immune assays to validate the biological relevance of the lipid A-based readout.
To prepare for future use (B), we will consolidate the intellectual property position; analyse the microbiome diagnostics and oncology market; and define the most viable commercialisation route, including licensing, service-based deployment or spin-off creation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Napoli Federico Ii | Napoli | Italy | Coordinator |
| Meta Group SRL | Roma | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI